Moreover, a numerical trend of better PFS outcomes among bone-only progressors compared to others, in our cohort, underlines the potential benefit of timely diagnosis (avoiding the potential risks and comorbidities associated with a late diagnosis) and early treatment intervention.
← all excerpts
Yearly Assessment of Bone Disease in Patients with Asymptomatic Multiple Myeloma Identifies Early Progression Events and Should Be the Standard Clinical Practice.
1
—
—